Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company advancing targeted therapies in precision oncology and metabolic disorders. This page serves as the definitive source for CRBP news, offering investors and researchers timely updates on scientific advancements and corporate developments.
Access verified information on clinical trial progress, regulatory milestones, and strategic partnerships across CRBP's pipeline. Key focus areas include Nectin-4 targeting antibody-drug conjugates, TGFβ pathway inhibitors, and novel obesity treatments designed to address critical unmet medical needs.
Our curated news collection enables efficient tracking of CRBP's innovative approaches to drug development. Stay informed about emerging data from studies evaluating CRB-701 in solid tumors, CRB-601's impact on tumor microenvironments, and CRB-913's potential in weight management.
Bookmark this page for direct access to official press releases and third-party analyses. Regular updates ensure you maintain current awareness of CRBP's position at the forefront of precision medicine development.
Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated dosing in a Phase 1 clinical trial for CRB-913, their second-generation CB1 inverse agonist targeting obesity treatment. The drug represents an advancement over first-generation treatments like rimonabant, which were discontinued due to neuropsychiatric side effects.
Pre-clinical data from Obesity Week 2024 shows CRB-913 is significantly more peripherally restricted, with a brain-to-plasma ratio 50 times lower than rimonabant and 15 times more peripherally restricted than monlunabant. The single ascending dose/multiple ascending dose (SAD/MAD) trial is expected to complete in Q3 2025, followed by a Phase 1b dose-range finding study scheduled for completion in H2 2026.
The company envisions potential applications for CRB-913 as a monotherapy, in combination with incretin analogs, or as maintenance therapy following incretin analog treatment.
Corbus Pharmaceuticals (NASDAQ: CRBP) has reported its Q4 and full-year 2024 financial results, highlighting significant pipeline progress. The company's CRB-701 Nectin-4 targeting ADC showed promising results in Phase 1 Western study and received FDA Fast Track Designation for metastatic cervical cancer treatment.
Financial highlights include a Q4 2024 net loss of $9.5 million ($0.78 per share), compared to $8.0 million ($1.81 per share) in Q4 2023. Full-year 2024 net loss was $40.2 million ($3.68 per share), an improvement from $44.6 million in 2023. Operating expenses increased by $2.5 million to $12.6 million in Q4 2024.
The company maintains a strong financial position with $149.1 million in cash and investments as of December 31, 2024, providing runway through Q3 2027. Their obesity program CRB-913 is scheduled to begin human dosing in March 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that CEO Yuval Cohen will participate in five upcoming investor conferences during February and March 2025. The company will be featured at:
- B. Riley Securities Precision Oncology & Radiopharma Conference (Feb 28) - participating in a panel on Nectin-4 Targeting Therapies
- TD Cowen 45th Annual Health Care Conference (Mar 4) - delivering a presentation with webcast availability
- Wedbush Securities Cardiometabolic Conference (Mar 10) - joining a panel on alternative obesity targets beyond GLP1s
- Leerink Partners Global Healthcare Conference (Mar 12) - presenting with webcast access
- BMO 2025 Obesity Summit (Mar 25) - participating in an Emerging Technologies panel
These appearances highlight Corbus' strategic focus on both oncology and obesity/cardiometabolic therapeutic areas, providing investors multiple opportunities to engage with company leadership.
Corbus Pharmaceuticals (NASDAQ:CRBP) presented Phase 1 study results for CRB-701 (SYS6002), a next-generation Nectin-4 targeting ADC, at ASCO-GU 2025. The Western study, conducted in the US and UK, mirrored the four highest doses used in the China study and showed comparable safety and PK profiles with no dose-limiting toxicities.
Key findings include: low levels of peripheral neuropathy (4% combined rate), positive clinical responses in urothelial (mUC) and cervical cancer patients, and notably, multiple responses in head and neck squamous cell carcinoma (HNSCC). The Western study enrolled 38 participants across eight tumor types, with 26 evaluable for efficacy. Dose optimization is ongoing at 2.7 mg/kg and 3.6 mg/kg Q3W.
The drug demonstrated encouraging safety with mainly grade 1 or 2 adverse events, and showed efficacy even in tumors with low Nectin-4 expression levels.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the release of abstract data from their first-in-human dose escalation clinical study of CRB-701 (SYS6002), which will be presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. The Western study, conducted in the US and Europe, includes updated data from 38 patients as of December 2024, expanding from the 31 patients covered in the September 2024 abstract.
The three-part Phase 1 study (NCT06265727) evaluates CRB-701's safety, pharmacokinetics, and efficacy in patients with advanced solid tumors showing high Nectin-4 expression. Part A evaluated four predetermined doses (1.8, 2.7, 3.6, and 4.5 mg/kg Q3W), followed by Parts B and C focusing on dose optimization and expansion to determine recommended doses and preliminary efficacy signals.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference, scheduled for February 5-6, 2025, in New York. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat discussion led by analysts and conduct one-on-one meetings with investors.
The presentation is set for February 5, 2025, at 2:30 PM. The format will include both the fireside discussion and individual investor meetings, with a webcast link provided for virtual attendance.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that data from its first-in-human dose escalation clinical study of CRB-701 (SYS6002) will be presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. The study, conducted in the US and UK, focuses on a next-generation Nectin-4 targeting antibody-drug conjugate.
The Phase 1 study (NCT06265727) consists of three parts and evaluates safety, pharmacokinetics, and efficacy in patients with advanced solid tumors showing high Nectin-4 expression. Part A of the study examined four predetermined doses: 1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg, and 4.5 mg/kg Q3W. The study will continue with Part B (dose optimization) and Part C (dose expansion) to determine recommended doses and assess preliminary efficacy.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, CA. CEO Yuval Cohen, Ph.D., will deliver a presentation on January 16, 2025, at 11:15 a.m. PST and will be available for one-on-one investor meetings during the conference.
The prestigious healthcare conference is an invitation-only event, and interested parties are advised to contact their J.P. Morgan representative for attendance details.
Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated the Phase 1 clinical trial of CRB-601, dosing its first patient for the treatment of advanced solid tumors. CRB-601 is a monoclonal antibody targeting latent TGFβ activation by blocking the integrin αVβ8.
Pre-clinical data has shown that CRB-601 successfully overcomes tumor immune exclusion and enhances the effectiveness of immune checkpoint inhibitors in vivo. The study (NCT06603844) represents a significant step in evaluating CRB-601's potential in immunotherapy and its ability to modulate TGFβ signaling.
Corbus Pharmaceuticals announced that the FDA has granted Fast Track designation to CRB-701 for treating relapsed or refractory metastatic cervical cancer. CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4, featuring a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE payload. The company has completed enrollment for the dose escalation portion of its Phase 1 clinical trial, which is evaluating safety, pharmacokinetics, and efficacy in patients with advanced solid tumors associated with high Nectin-4 expression. Initial data from the dose escalation study is expected in Q1 2025.
